Sub menu

 
 

Bevacip/Bevaciptin

Sponsor
Cipla Australia Pty Ltd
ARTGs
347290, 347291, 347292 and 347293
347290, 347291, 347292 and 347293
347290, 347291, 347292 and 347293
347290, 347291, 347292 and 347293
Device/Product name
Bevacip/Bevaciptin
Active Ingredient
Bevacizumab
Date of decision
Published
Submission type
New biosimilar medicine
ATC codes
L01XC07
Decision
Approved
What was the decision based on
The decision was based on quality (chemistry and manufacturing), nonclinical (pharmacology and toxicology) and clinical (pharmacology, safety and efficacy) information submitted by the sponsor. The benefit-risk profile of Bevacip/Bevaciptin was considered favourable for the therapeutic use approved.
What steps were involved in the decision process

Registration timeline

The following table summarises the key steps and dates for this application.

Description Date
Submission dossier accepted and first round evaluation commenced 30 November 2020
First round evaluation completed 30 April 2021
Sponsor provides responses on questions raised in first round evaluation 30 June 2021
Second round evaluation completed 9 August 2021
Delegate's overall benefit-risk assessment 6 October 2021
Sponsor's pre-Advisory Committee response Not applicable
Advisory Committee meeting Not applicable
Registration decision (Outcome) 13 October 2021
Completion of administrative activities and registration on ARTG 2 November 2021
Number of working days from submission dossier acceptance to registration decision* 172

*Statutory timeframe for standard applications is 255 working days

Date of entry onto ARTG
Original publication date
Black triangle scheme
No
Dose forms
Concentrated solution for infusion
Strength
25 mg/mL (100 mg/4 mL or 400 mg/16 mL)
Other ingredients
Trehalose dehydrate, monobasic sodium phosphate monohydrate, dibasic sodium phosphate, polysorbate 20, and water for injections
Containers
Vial
Pack sizes
One (100 mg/4 ml or 400 mg/16 mL vial)
Routes of administration
Intravenous
Dosage

The recommended dosage of Bevacip/Bevaciptin is based on multiple factors, including the condition being treated, the body weight and the age of the patient.

Bevacip/Bevaciptin should be administered under the supervision of a physician experienced in the use of anti‑neoplastic medicinal products.

For further information refer to the Product Information.

Pregnancy category
DDrugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.The use of any medicine during pregnancy requires careful consideration of both risks and benefits by the treating health professional. This must not be used as the sole basis of decision making in the use of medicines during pregnancy. The TGA does not provide advice on the use of medicines in pregnancy for specific cases. More information is available from obstetric drug information services in your State or Territory.
What was approved

Bevacip/Bevaciptin (bevacizumab) was approved for the following therapeutic use:

Metastatic colorectal cancer

Bevacip/Bevaciptin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.

Locally recurrent or metastatic breast cancer

Bevacip/Bevaciptin (bevacizumab) in combination with paclitaxel is indicated for the first line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated (see section 5.1 Clinical trials).

Advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)

Bevacip/Bevaciptin (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non-small cell lung cancer.

Advanced and/or metastatic renal cell cancer

Bevacip/Bevaciptin (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer.

Grade IV glioma

Bevacip/Bevaciptin (bevacizumab) as a single agent, is indicated for the treatment of patients with Grade IV glioma after relapse or disease progression after standard therapy, including chemotherapy.

Epithelial ovarian, fallopian tube or primary peritoneal cancer

Bevacip/Bevaciptin (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (FIGO stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

Bevacip/Bevaciptin (bevacizumab) in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other VEGF-targeted angiogenesis inhibitors.

Bevacip/Bevaciptin (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti angiogenic therapy including bevacizumab.

Cervical cancer

Bevacip/Bevaciptin (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. Bevacip/Bevaciptin (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

What is this medicine and how does it work
Bevacip/Bevaciptin is an antineoplastic agent containing the active ingredient, bevacizumab. Bevacizumab is a recombinant humanised monoclonal antibody that selectively binds to and neutralises the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions with antigen binding regions of a humanised murine antibody that binds to VEGF. Bevacizumab is produced by recombinant deoxyribonucleic acid (DNA) technology in a Chinese hamster ovary mammalian cell expression system and is purified by a process that includes specific viral inactivation and removal steps.Bevacizumab inhibits the binding of VEGF to its receptors, fms-like tyrosine kinase 1 (Flt-1) and kinase insert domain receptor (KDR), on the surface of endothelial cells. Neutralising the biologic activity of VEGF reduces the vascularisation of tumours, thereby inhibiting tumour growth. Administration of bevacizumab or its parental murine antibody to xenotransplant models of cancer in nude mice resulted in extensive anti-tumour activity in human cancers, including colon, breast, pancreas and prostate. Metastatic disease progression was inhibited, and microvascular permeability was reduced.
What post-market commitments will the sponsor undertake
  • This approval does not impose any requirement for the submission of periodic safety update reports (PSURs). The sponsor should note that it is a requirement that all existing requirements for the submission of PSURs as a consequence of the initial registration or subsequent changes must be completed.
  • For all injectable products the Product Information must be included with the product as a package insert.

Help us improve the Therapeutic Goods Administration site